Literature DB >> 10461545

FK506 and the role of the immunophilin FKBP-52 in nerve regeneration.

B G Gold1.   

Abstract

In summary, FKBP-12 does not mediate the neurite outgrowth-promoting properties of neuroimmunophilin ligands (e.g., FK506). Instead, the neurotrophic properties of neuroimmunophilin ligands (FK506) and steroid hormones are mediated by disruption of steroid-receptor complexes. It remains unclear which component mediates neurite outgrowth, although the most likely candidates are FKBP-52, hsp-90, and p23 [42]. Regardless of the underlying mechanism involved, the FKBP-52 antibody data reveal that it should be possible to design, based on the structure of FK506, non-FKBP-12-binding (nonimmunosuppressant) compounds selective for FKBP-52 and test these new libraries for their ability to augment nerve regeneration. It may also be possible to exploit the structure of geldanamycin to develop a new class of hsp-90-binding compounds for use in nerve regeneration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10461545     DOI: 10.1081/dmr-100101940

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  14 in total

1.  Effects of altered cyclophilin A expression on growth and differentiation of human and mouse neuronal cells.

Authors:  P Nahreini; A R Hovland; B Kumar; C Andreatta; J Edwards-Prasad; K N Prasad
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

2.  The effects of cold preservation and subimmunosuppressive doses of FK506 on axonal regeneration in murine peripheral nerve isografts.

Authors:  Terence M Myckatyn; Daniel A Hunter; Susan E Mackinnon
Journal:  Can J Plast Surg       Date:  2003

3.  Tissue engineered constructs for peripheral nerve surgery.

Authors:  P J Johnson; M D Wood; A M Moore; S E Mackinnon
Journal:  Eur Surg       Date:  2013-06       Impact factor: 0.953

4.  Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs.

Authors:  J G Lunz; S Contrucci; K Ruppert; N Murase; J J Fung; T E Starzl; A J Demetris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 5.  Unraveling the role of peptidyl-prolyl isomerases in neurodegeneration.

Authors:  Melanie Gerard; Angélique Deleersnijder; Jonas Demeulemeester; Zeger Debyser; Veerle Baekelandt
Journal:  Mol Neurobiol       Date:  2011-05-07       Impact factor: 5.590

6.  Comparing electrical stimulation and tacrolimus (FK506) to enhance treating nerve injuries.

Authors:  Sally Jo; Deng Pan; Alexandra E Halevi; Joseph Roh; Lauren Schellhardt; Daniel A Hunter Ra; Alison K Snyder-Warwick; Amy M Moore; Susan E Mackinnon; Matthew D Wood
Journal:  Muscle Nerve       Date:  2019-08-21       Impact factor: 3.217

7.  Activation of BMP Signaling by FKBP12 Ligands Synergizes with Inhibition of CXCR4 to Accelerate Wound Healing.

Authors:  Brandon J Peiffer; Le Qi; Ali R Ahmadi; Yuefan Wang; Zufeng Guo; Hanjing Peng; Zhaoli Sun; Jun O Liu
Journal:  Cell Chem Biol       Date:  2019-02-28       Impact factor: 8.116

8.  Subcellular rearrangement of hsp90-binding immunophilins accompanies neuronal differentiation and neurite outgrowth.

Authors:  Héctor R Quintá; Darío Maschi; Celso Gomez-Sanchez; Graciela Piwien-Pilipuk; Mario D Galigniana
Journal:  J Neurochem       Date:  2010-09-28       Impact factor: 5.372

9.  Role of timing in assessment of nerve regeneration.

Authors:  Michael J Brenner; Arash Moradzadeh; Terence M Myckatyn; Thomas H H Tung; Allen B Mendez; Daniel A Hunter; Susan E Mackinnon
Journal:  Microsurgery       Date:  2008       Impact factor: 2.425

10.  Treatment modality affects allograft-derived Schwann cell phenotype and myelinating capacity.

Authors:  Ayato Hayashi; Arash Moradzadeh; Alice Tong; Cindy Wei; Sami H Tuffaha; Daniel A Hunter; Thomas H Tung; Alexander Parsadanian; Susan E Mackinnon; Terence M Myckatyn
Journal:  Exp Neurol       Date:  2008-04-25       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.